Vivo Ventures Fund VII, L.P.'s Form 4 filing
Sierra Oncology, Inc. (SRRA) · filed Jan 31, 2022
- Accession no.
- 0001213900-22-004647
- Filed
- Jan 31, 2022, 9:30 PM ET
- Trade date
- Jan 31, 2022
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market purchases total $21.6M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Vivo Ventures Fund VII, L.P.CIK 0001509160 | 10% Owner |
| Vivo Ventures VII Affiliates Fund, L.P.CIK 0001538309 | 10% Owner |
| Vivo Ventures VII, LLCCIK 0001565020 | 10% Owner |
| Vivo Opportunity Fund, L.P.CIK 0001726403 | 10% Owner |
| Vivo Opportunity, LLCCIK 0001728970 | 10% Owner |
| Vivo Capital Fund IX, L.P.CIK 0001750117 | 10% Owner |
| Vivo Capital IX, LLCCIK 0001750698 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 31, 2022 | Common Stock | PPurchaseAcquired | +800,000 | $27.00 | +$21,600,000 | 2,735,853 | Indirect | Duplicate filing |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.